Dermata Therapeutics Inc Cash Flow Conversion Efficiency
Dermata Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has a cash flow conversion efficiency ratio of -0.694x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.42 Million) by net assets ($3.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dermata Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2025. This chart illustrates how Dermata Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Dermata Therapeutics Inc for real-time trading data and today's change.
Dermata Therapeutics Inc Cash Flow Conversion Ratio Explained
Dermata Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dermata Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermata Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Dermata Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maple Peak Investments Inc
V:MAP
|
-0.062x |
|
Pinnacle Minerals Ltd
AU:PIM
|
-0.106x |
|
J-Star Holding Co., Ltd. Ordinary Shares
NASDAQ:YMAT
|
0.351x |
|
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
NASDAQ:AZI
|
-0.029x |
|
Hochdorf Holding AG
SW:HOCN
|
-0.550x |
|
Focus Universal Inc
NASDAQ:FCUV
|
-6.068x |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
-0.567x |
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
0.838x |
Annual Cash Flow Conversion Efficiency for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2025. Review Dermata Therapeutics Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.22 Million | $-7.76 Billion | -1246.519x | -17332.07% |
| 2024-12-31 | $1.56 Million | $-11.16 Million | -7.151x | -609.06% |
| 2023-12-31 | $6.36 Million | $-6.41 Million | -1.008x | +31.26% |
| 2022-12-31 | $6.02 Million | $-8.83 Million | -1.467x | -160.43% |
| 2021-12-31 | $10.11 Million | $-5.69 Million | -0.563x | -144.44% |
| 2020-12-31 | $-3.18 Million | $-4.03 Million | 1.268x | -93.21% |
| 2019-12-31 | $-210.16K | $-3.92 Million | 18.663x | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more